Acticor Biotech SAS Stock Euronext Paris

Stocks

FR0014005OJ5

Biotechnology & Medical Research

Real-time Euronext Paris 09:36:28 2024-12-09 EST 5-day change 1st Jan Change
0.2500 EUR -1.96% Intraday chart for Acticor Biotech SAS -13.79% -
Manager TitleAgeSince
Chief Executive Officer - 2013-11-25
Director of Finance/CFO 68 2024-10-12
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 2013-11-25
Director/Board Member 66 2018-10-23
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.96%-13.79% - - 12.69M
-0.38%+0.40%+71.69%+128.83% 56.71B
+4.91%-3.30%+71.97%+92.14% 51.3B
+1.48%+10.52%+23.01%+495.47% 25.26B
-0.59%-1.00%-16.73%-12.99% 23.65B
+3.93%+7.11%+44.20%-1.96% 18.69B
+2.01%+7.22%+41.55%-24.93% 17.71B
-6.84%+4.81%+201.88%+348.11% 17.7B
-0.92%+8.90%+38.48% - 14.26B
+1.76%+5.82%+31.23%+195.70% 14.1B
Average +0.49%+3.45%+56.37%+152.55% 26.6B
Weighted average by Cap. +1.22%+2.16%+58.77%+145.18%
Logo Acticor Biotech SAS
Acticor Biotech is specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II/III clinical development (Glenzocimab).
Employees
-